1. PRIVATE & CONFIDENTIAL
Designed selection
criteria for Phase III
trials to reduce cost
by up to 12%.
DATAX > DEVELOPX > DEPLOYX
CHALLENGE
ACTION
Phase III clinical drug trials require tests on hundreds of thousands
of patients and are very high-cost. The participant selection criteria
for Phase III trials could be made more precise using patients’
genetic information, Phase II trial information, and patient
responses, resulting in faster and more cost-effective trials.
DATAX
CrowdANALYTIX collected responses from patients during Phase II trials along with
their genetic information. This data was obfuscated for compliance with HIPAA to
ensure full patient privacy.
DEVELOPX
Predictive models were created to predict which patients were likely to have
worsening symptoms of their preexisting conditions due to the intervention in the trial.
Top variables which could help identify and monitor exacerbation of disease based on
the model output were uncovered.
DEPLOYX
CrowdANALYTIX deployed the optimal model both to determine selection criteria for
Phase III trials and predict potential reaction for each patient in the clinical trial.
PHARMACEUTICALS
PATIENT RESPONSES
DATA USED
GENETIC INFORMATION
1
